#United States #New York #Securities Class Action #Sarepta Therapeutics #ELEVIDYS therapy

Legal Action Against Sarepta Therapeutics, Inc.

The Gross Law Firm has announced important news for shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) with the initiation of a securities class action lawsuit. This legal action stems from serious allegations against the company regarding the misleading information provided to investors, particularly concerning their gene therapy, ELEVIDYS.

Understanding the Allegations

According to the allegations, Sarepta Therapeutics misled investors during the class period from June 22, 2023, to June 24, 2025. The complaint outlines several key points that may have serious implications for shareholders:

1. Health Risks: It asserts that ELEVIDYS, which is a prescription gene therapy for Duchenne Muscular Dystrophy, poses significant safety risks that were not disclosed adequately.

2. Failure to Detect Side Effects: The assertion includes claims that the trial protocols for ELEVIDYS failed to recognize severe adverse side effects, raising concerns about the effectiveness and safety of the therapy.

3. Halting of Trials: Due to the severity of adverse events observed from ELEVIDYS treatments, the company was forced to halt patient recruitment and dosing in clinical trials. This development could attract regulatory scrutiny and significantly affect the therapy's approvals and market prospects.

4. Investor Misinformation: The allegations claim that Sarepta’s executives issued positive statements lacking a reasonable foundation, leading to artificial inflation of the company’s stock price, which ultimately misled investors.

Call to Action for Shareholders

Sarepta shareholders who acquired shares within the specified class period are urged to register their information with The Gross Law Firm. The deadline to potentially become a lead plaintiff in the case is August 25, 2025. Participation in the class action does not require shareholders to be lead plaintiffs, offering a more accessible path for those who have faced financial losses.

After registration, shareholders will benefit from portfolio monitoring software that provides updates and necessary information throughout the case's lifecycle.

Why Choose The Gross Law Firm?

The Gross Law Firm is renowned for its commitment to protecting investors' rights and providing a path toward recovery for those who have suffered due to misleading corporate practices. The firm stands against deceit and fraud in the corporate domain, advocating for responsible business operations and investor transparency. Their concerted efforts aim to ensure that such incidents do not compromise the integrity of the financial markets.

The legal action not only seeks to bring justice to affected investors but also strives to hold Sarepta accountable for its alleged misleading actions regarding the safety and effectiveness of ELEVIDYS. Shareholders are encouraged to act swiftly and ensure that their voices are heard.

Next Steps for Investors

Interested shareholders can easily register their information through the following link to secure their position in this critical class action lawsuit: Sarepta Class Action Registration. Remember, the clock is ticking, so act before the deadline of August 25, 2025.

Conclusion

In conclusion, the unfolding developments surrounding Sarepta Therapeutics and the ELEVIDYS therapy underscore the importance of vigilance among investors in understanding the risks and realities of their investments. The Gross Law Firm is dedicated to guiding shareholders through this legal landscape, advocating for accountability, and protecting investor interests. Now is the time for impacted shareholders to step forward and make their voices count in this class action.